Metformin Attenuates Glucose-Driven Hepatocellular Carcinoma Progression by Targeting GPD2-Mediated Metabolic Plasticity.
4 affiliations
- 1Department of Biology Faculty of Science Chulalongkorn University Bangkok 10330 Thailand chula.ac.th.
- 2Bioinformatics and Computational Biology Program Graduate School Chulalongkorn University Bangkok 10330 Thailand chula.ac.th.
- 3Department of Biochemistry Faculty of Medicine Khon Kaen University Khon Kaen 40002 Thailand kku.ac.th.
- 4Center of Excellence in Systems Biology Faculty of Medicine Chulalongkorn University Bangkok 10330 Thailand chula.ac.th.
Abstract
Glucose metabolism is crucial for cancer cell survival and proliferation. Hepatocellular carcinoma (HCC) cells exhibit distinct metabolic adaptations that support tumor progression under nutrient-limited conditions. The study examines the impact of glucose availability and GPD2-mediated metabolic adaptation on HCC progression, as well as how these processes are modulated by glucose transport inhibitors and metformin. Cell proliferation and migration of HCC cells (HepG2 and Huh7) and lung cancer cells (A549) were examined under different glucose concentrations using MTT, colony formation, and scratch assays. The impacts of glucose transporter 1 (GLUT1) inhibitors and metformin were also evaluated. Gene and protein expression data were analyzed from TCGA/CPTAC datasets, and GPD2 expression was validated by immunohistochemistry. High glucose enhanced proliferation and migration of liver cancer cells. Unlike A549, HepG2 and Huh7 cells maintained growth under glucose deprivation, indicating metabolic plasticity. GPD2 was markedly upregulated in HCC tissues and correlated with poor survival. Metformin suppressed cell proliferation and migration in a dose-dependent manner, with stronger effects under low-glucose conditions. Mechanistically, metformin downregulated Cyclin D1 and XIAP, induced Caspase-3 cleavage, and reduced the EMT marker, Slug. Correlation analyses revealed positive associations between GPD2 and CCND1 or SNAI2, indicating a link between GPD2 and cell cycle and EMT signaling. In conclusion, HCC cells utilize GPD2-mediated metabolic adaptation to sustain growth under glucose-limiting conditions. GPD2 represents a prognostic biomarker and therapeutic target in HCC. Metformin effectively inhibits HCC progression by disrupting GPD2-linked pro-survival and EMT pathways.
Related
- CircFAM65A/CANX Condensates Sequester FAM134B to Inhibit ER‐phagy and Suppress Hepatocellular Carcinoma Progression
- The Role of METTL3-Mediated m⁶A Methylation in Hepatocellular Carcinoma Progression and Treatment.
- Stachydrine Hydrochloride Suppresses Hepatocellular Carcinoma Progression by Reprogramming Macrophage Polarization Through the LIF/PI3K/Akt Axis
- Mechanistic insights into ENO2-driven glycolysis and tumor progression in hepatocellular carcinoma
- CircUGP2 inhibits tumor progression via PI3K/AKT/mTOR signaling through sponging miR-137-3p and interacting with UPF1 in hepatocellular carcinoma
BibTeX
@article{siripongsampan2026metformin,
title = {{Metformin Attenuates Glucose-Driven Hepatocellular Carcinoma Progression by Targeting GPD2-Mediated Metabolic Plasticity.}},
author = {Supakant Siripongsampan and Manusanun Kateyai and Kanadit Piriyapairoje and Jantanipa Hannam and Charupong Saengboonmee and Teeranai Ittiudomrak and Sukanya Jaroenporn and Sittiporn Pattaradilokrat and Chatchai Phoomak},
journal = {Scientifica},
year = {2026},
month = oct,
doi = {10.1155/sci5/9372425},
url = {https://europepmc.org/article/MED/42948351},
note = {CC BY},
}
RIS
TY - JOUR
TI - Metformin Attenuates Glucose-Driven Hepatocellular Carcinoma Progression by Targeting GPD2-Mediated Metabolic Plasticity.
AU - Supakant Siripongsampan
AU - Manusanun Kateyai
AU - Kanadit Piriyapairoje
AU - Jantanipa Hannam
AU - Charupong Saengboonmee
AU - Teeranai Ittiudomrak
AU - Sukanya Jaroenporn
AU - Sittiporn Pattaradilokrat
AU - Chatchai Phoomak
PY - 2026
DA - 2026/10/27
JO - Scientifica
DO - 10.1155/sci5/9372425
UR - https://europepmc.org/article/MED/42948351
AB - Glucose metabolism is crucial for cancer cell survival and proliferation. Hepatocellular carcinoma (HCC) cells exhibit distinct metabolic adaptations that support tumor progression under nutrient-limited conditions. The study examines the impact of glucose availability and GPD2-mediated metabolic adaptation on HCC progression, as well as how these processes are modulated by glucose transport inhibitors and metformin. Cell proliferation and migration of HCC cells (HepG2 and Huh7) and lung cancer cells (A549) were examined under different glucose concentrations using MTT, colony formation, and scratch assays. The impacts of glucose transporter 1 (GLUT1) inhibitors and metformin were also evaluated. Gene and protein expression data were analyzed from TCGA/CPTAC datasets, and GPD2 expression was validated by immunohistochemistry. High glucose enhanced proliferation and migration of liver cancer cells. Unlike A549, HepG2 and Huh7 cells maintained growth under glucose deprivation, indicating metabolic plasticity. GPD2 was markedly upregulated in HCC tissues and correlated with poor survival. Metformin suppressed cell proliferation and migration in a dose-dependent manner, with stronger effects under low-glucose conditions. Mechanistically, metformin downregulated Cyclin D1 and XIAP, induced Caspase-3 cleavage, and reduced the EMT marker, Slug. Correlation analyses revealed positive associations between GPD2 and CCND1 or SNAI2, indicating a link between GPD2 and cell cycle and EMT signaling. In conclusion, HCC cells utilize GPD2-mediated metabolic adaptation to sustain growth under glucose-limiting conditions. GPD2 represents a prognostic biomarker and therapeutic target in HCC. Metformin effectively inhibits HCC progression by disrupting GPD2-linked pro-survival and EMT pathways.
SN - 2090-908X
ER -